Non-Alcoholic Steatohepatitis (NASH) Market Report 2026

Non-Alcoholic Steatohepatitis (NASH) Market Overview

• Non-Alcoholic Steatohepatitis (NASH) market size has reached to $6.06 billion in 2025 • Expected to grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 31.9% • Growth Driver: The Growing Demand For NASH Treatment Amid Obesity Epidemic • Market Trend: Innovative Therapeutic Approaches for Liver Health • North America was the largest region in 2025.

What Is Covered Under Non-Alcoholic Steatohepatitis (NASH) Market?

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure. The main types of non-alcoholic steatohepatitis (NASH) are solid and liquid. Solid is primarily created as crystalline solid forms that are sold as tablets for oral consumption, due to its excellent purity and durability. The products involved are vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib, and cenicriviroc, and others that are used for different disease causes such as hypertension, heart disease, high blood lipid, type 2 diabetes, obesity, and sold by the hospital pharmacy, retail pharmacy, online providers. It includes oral and parenteral applications.

What Is The Non-Alcoholic Steatohepatitis (NASH) Market Growth Forecast?

The non-alcoholic steatohepatitis (nash) market size is expected to see exponential growth in the next few years. It will grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 31.9%. The growth in the forecast period can be attributed to advancements in targeted therapies, increased healthcare expenditure, growing adoption of non-invasive diagnostics, expansion of pharmaceutical pipelines, rising collaborations for r&d. Major trends in the forecast period include rising prevalence of obesity and type 2 diabetes, development of non-invasive diagnostic tools, increasing research in liver fibrosis therapies, growth in personalized and targeted drug treatments, expansion of hospital and retail pharmacy networks.

Global Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

1) By Dosage Form: Solid, Liquid 2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products 3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity 4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider 5) By Application: Oral, Parenteral Subsegments: 1) By Solid: Tablets, Capsules, Other Solid Dosage Forms 2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

What Is The Driver Of The Non-Alcoholic Steatohepatitis (NASH) Market?

The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As non-alcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in May 2025, according to the Government Digital Service, a UK-based government body, In 2023 to 2024, the prevalence of overweight (including obesity) in adults was higher among men (69.7%) than women (59.2%), while the prevalence of obesity in adults was higher among women (26.9%) than men (26.2%). Therefore, the rise in the cases of obesity will drive the growth of the non-alcoholic steatohepatitis (NASH) industry.

Key Players In The Global Non-Alcoholic Steatohepatitis (NASH) Market

Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens

Global Non-Alcoholic Steatohepatitis (NASH) Market Trends and Insights

Major companies operating in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that selectively activate the thyroid hormone receptor-beta subtype, which is a key receptor involved in the regulation of metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist as the first treatment for adults with noncirrhotic NASH with moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra helps regulate lipid metabolism, leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.

What Are Latest Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market?

In April 2024, Novo Nordisk A/S, a Denmark-based global healthcare company, formed research collaborations with Omega Therapeutics and Cellarity to explore novel treatment approaches for cardiometabolic diseases. The collaboration aims to accelerate the discovery and development of innovative therapies targeting metabolic and cardiovascular conditions, enhancing patient outcomes while fostering innovation and growth in the cardiometabolic disease space. Omega Therapeutics is a US-based biotechnology company specializing in gene control therapeutics, and Cellarity is a US-based biotech firm focused on cell reprogramming-based drug discovery.

Regional Insights

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Alcoholic Steatohepatitis (NASH) Market?

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Alcoholic Steatohepatitis (NASH) Market Report 2026?

The non-alcoholic steatohepatitis (nash) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (nash) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.